CenterWatch

Clinical Trial Details

Overview

Research Study Summary

A Phase III, multi-center randomized, 24 week, double-blind, parallel group, placebo controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period

Purpose

The purpose of this research study is to investigate if an experimental drug, R04917838, is effective at reducing negative symptoms of schizophrenia when added to your current antipsychotic treatment.

Please contact Alexian Brothers for more information on participation.

To Learn more

CW ID:176877
Date Last Changed: July 22, 2013

Clinical Trial Snapshot

Phase
3
Gender
Both Male and Female
Age
N/A
Overall Status
Recruiting
Duration
24 Weeks
Facility Type
N/A

Contact

Alexian Brothers Hospital Network
1786 Moon Lake Boulevard, Suite 200
Hoffman Estates, IL 60169
Phone: 847-230-3599

View Map

Research Center Information: Alexian Brothers Hospital Network

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.